Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13G/A

Standard BioTools Inc.

LABNASDAQEQUITYCurrent

Beneficial Ownership Report

Filed Nov 16, 2026Accepted Nov 16, 2026, 4:00 PM ESTFiling CIK 1162194Accession 0001019056-26-000164
Share

Structured filing — SCHEDULE 13G/A

primary_doc.xml

Open full document ↗

Amendment · This filing reports the amendment as submitted.

Subject company

Company
STANDARD BIOTOOLS INC.
Company CIK
0001162194
Street
50 MILK STREET
Street (continued)
10TH FLOOR
City
BOSTON
State / country code
MA
Postal code
02109

Statement details

Amendment number
3
Security class
Common Stock, $0.001 par value per share
Event date
09/30/2026
Rule designation
Rule 13d-1(c)

Reporting person 1

Name
MAK Capital Fund LP
Citizenship / organization
D0
Reporting person type
PN
Group designation
a
Aggregate amount owned
24,979,153.00
Percent of class
6.3
Sole voting power
0.00
Shared voting power
24,979,153.00
Sole dispositive power
0.00
Shared dispositive power
24,979,153.00
Aggregate excludes certain shares
N
Comments
The calculation is based upon 24,979,153 shares of Common Stock beneficially owned as of 09/30/2026 and a total of 394,790,441 shares of Common Stock, $0.001 par value per share, outstanding as of November 1, 2026, as reported by the Issuer on its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 3, 2026.

Reporting person 2

Name
MAK CAPITAL ONE LLC
Citizenship / organization
DE
Reporting person type
IA
Group designation
a
Aggregate amount owned
24,979,153.00
Percent of class
6.3
Sole voting power
0.00
Shared voting power
24,979,153.00
Sole dispositive power
0.00
Shared dispositive power
24,979,153.00
Aggregate excludes certain shares
N
Comments
The calculation is based upon 24,979,153 shares of Common Stock beneficially owned as of 09/30/2026 and a total of 394,790,441 shares of Common Stock, $0.001 par value per share, outstanding as of November 1, 2026, as reported by the Issuer on its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 3, 2026.

Reporting person 3

Name
Kaufman Michael A
Citizenship / organization
X1
Reporting person type
IN
Group designation
a
Aggregate amount owned
24,979,153.00
Percent of class
6.3
Sole voting power
0.00
Shared voting power
24,979,153.00
Sole dispositive power
0.00
Shared dispositive power
24,979,153.00
Aggregate excludes certain shares
N
Comments
The calculation is based upon 24,979,153 shares of Common Stock beneficially owned as of 09/30/2026 and a total of 394,790,441 shares of Common Stock, $0.001 par value per share, outstanding as of November 1, 2026, as reported by the Issuer on its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 3, 2026.

Item 1

Issuer

STANDARD BIOTOOLS INC.

Principal executive office address

50 MILK STREET, 10TH FLOOR, BOSTON, MASSACHUSETTS, 02109.

Item 2

Citizenship

MAK Capital Fund LP is a Bermuda limited partnership. MAK Capital One L.L.C. is a Delaware limited liability company. Mr. Kaufman is a United States citizen.

Filing person

This Schedule 13G/A is being filed by: i. MAK Capital Fund LP ("MAK Fund") ii. MAK Capital One L.L.C. ("MAK Capital"); and iii. Michael A. Kaufman ("Mr. Kaufman," and collectively with MAK Fund and MAK Capital, the "Reporting Persons")

Principal business or residence address

The principal business address of (i) MAK Fund is c/o Wakefield Quin, Victoria Place, 31 Victoria Street, Bermuda; and (ii) MAK Capital and Mr. Kaufman is 590 Madison Avenue, 31st Floor, New York, NY 10022.

Item 3

Not applicable indication

Y

Item 4

Percent of class

6.3% The calculation is based upon 24,979,153 shares of Common Stock beneficially owned as of 09/30/2026 and a total of 394,790,441 shares of Common Stock, $0.001 par value per share, outstanding as of November 1, 2026, as reported by the Issuer on its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 3, 2026.

Amount beneficially owned

24,979,153

Sole voting power

0

Shared voting power

24,979,153

Sole dispositive power

0

Shared dispositive power

24,979,153

Item 5

Not applicable indication

Y

Item 6

Not applicable indication

Y

Item 7

Not applicable indication

Y

Item 8

Not applicable indication

Y

Item 9

Not applicable indication

Y

Item 10

Not applicable indication

N

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Signature 1

Reporting person
MAK Capital Fund LP
Signed
/s/ Michael A. Kaufman
Title
Managing Member
Date
11/16/2026

Signature 2

Reporting person
MAK CAPITAL ONE LLC
Signed
/s/ Michael A. Kaufman
Title
Managing Member
Date
11/16/2026

Signature 3

Reporting person
Kaufman Michael A
Signed
/s/ Michael A. Kaufman
Title
Michael A. Kaufman
Date
11/16/2026

Filed exhibits

Company context

Standard BioTools Inc. (NASDAQ: LAB), is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world class management team. Standard BioTools’ established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.

Current securities

Historical securities (1)

Recent company filings

  1. 425 filingNov 16, 2026
  2. Other EventsNov 16, 2026
  3. 10-Q filingNov 3, 2026
  4. 425 filingNov 3, 2026
  5. Regulation FD DisclosureNov 3, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.